News
CGTX
1.960
+1.03%
0.020
Cognition Therapeutics To Be Issued US patent Number 11,981,636 Titled "COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES (INCLUDING ALZHEIMER'S DISEASE AND COGNITIVE DECLINE)"
Benzinga · 5d ago
Oppenheimer Sticks to Their Buy Rating for Cognition Therapeutics (CGTX)
TipRanks · 5d ago
Weekly Report: what happened at CGTX last week (0506-0510)?
Weekly Report · 5d ago
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024
Cognition Therapeutics reported earnings per share of -27 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -29 cents. CognitionTherapeutics just reported results.
Investorplace · 05/07 17:53
Cognition Therapeutics, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/07 12:33
Cognition Therapeutics GAAP EPS of -$0.27
Seeking Alpha · 05/07 12:04
COGNITION THERAPEUTICS Q1 OPERATING EXPENSES USD 14.102 MILLION
Reuters · 05/07 11:30
COGNITION THERAPEUTICS INC: TOPLINE RESULTS FROM SHINE STUDY IN MILD-TO-MODERATE ALZHEIMER'S EXPECTED MID-2024
Reuters · 05/07 11:30
Press Release: Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update. Topline results from SHINE Study in Mild-to-Moderate Alzheimer's Expected mid-2024. SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants.
Dow Jones · 05/07 11:30
Press Release: Cognition Therapeutics Reports -2-
As of March 31, 2016, the company had a total of 33,735,269 shares of common stock outstanding. The company has a market capitalization of $1.2 billion. The Company has no debt and no liabilities. The stock is trading at a premium to the value of the common shares.
Dow Jones · 05/07 11:30
Weekly Report: what happened at CGTX last week (0429-0503)?
Weekly Report · 05/06 10:38
Cognition Therapeutics Inc <CGTX.OQ> expected to post a loss of 25 cents a share - Earnings Preview
Cognition Therapeutics Inc expected to post a loss of 25 cents a share. The company is expected to show change in quarterly revenue when it reports results on May 4. The average analyst rating on the shares is "buy" and the median 12-month price target is $6.00.
Reuters · 05/02 11:02
COGNITION THERAPEUTICS INC: TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2024 AFTER LAST PARTICIPANTS HAVE COMPLETED SIX MONTHS OF TREATMENT
Reuters · 04/29 11:31
Weekly Report: what happened at CGTX last week (0422-0426)?
Weekly Report · 04/29 10:43
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
Cognition Therapeutics, Inc. Has reached target enrollment in the randomized, placebo-controlled Phase 2 SHIMMER study. Top-line results are expected in the second half of 2024. The study is examining the safety and effectiveness of CT1812 in adults with mild-to-moderate dementia with Lewy bodies.
Barchart · 04/29 06:30
12 Health Care Stocks Moving In Monday's After-Market Session
Nuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. Sensei Biotherapeutics and Cognition Therapeutics among the gainers. Losers include Phio Pharma and Rigel Pharmaceuticals.
Benzinga · 04/22 20:31
Weekly Report: what happened at CGTX last week (0415-0419)?
Weekly Report · 04/22 10:36
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
Cognition Therapeutics, Inc. Is a clinical stage company developing drugs that treat neurodegenerative disorders. The virtual KOL event will be held on April 12, 2024. Cognition will provide a recap of the virtual event hosted by the NYU School of Medicine.
Barchart · 04/22 06:30
More
Webull provides a variety of real-time CGTX stock news. You can receive the latest news about COGNITION THERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About CGTX
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. It is developing other product candidates in the area of synucleinopathies.